Tweedy Browne Co LLC Has $37.38 Million Stock Position in Johnson & Johnson $JNJ

Key Points

• Tweedy Browne Co LLC has reduced its stake in Johnson & Johnson by 44.2% during the second quarter, now owning a stock position valued at $37.38 million.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, representing an annualized dividend of $5.20 and a yield of 2.7%.
• The company's stock has a market capitalization of $465.45 billion with a PE ratio of 18.65 and a consensus price target of $199.59 from analysts.

Tweedy Browne Co LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 44.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 244,713 shares of the company's stock after selling 193,558 shares during the quarter. Johnson & Johnson comprises about 3.5% of Tweedy Browne Co LLC's investment portfolio, making the stock its 8th largest holding. Tweedy Browne Co LLC's holdings in Johnson & Johnson were worth $37,380,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. GFG Capital LLC bought a new position in Johnson & Johnson during the 2nd quarter valued at $35,000. Stone House Investment Management LLC bought a new position in Johnson & Johnson during the first quarter valued at about $47,000. 1248 Management LLC bought a new position in Johnson & Johnson during the first quarter valued at about $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson in the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson in the 1st quarter valued at about $52,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $193.27 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market cap of $465.45 billion, a PE ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The business has a fifty day simple moving average of $180.49 and a 200-day simple moving average of $164.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio (DPR) is currently 50.19%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on JNJ. Argus set a $210.00 target price on shares of Johnson & Johnson in a report on Wednesday. Citigroup upped their price target on Johnson & Johnson from $213.00 to $215.00 and gave the company a "buy" rating in a report on Wednesday. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. lifted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Tuesday, September 16th. Finally, Wall Street Zen raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $199.59.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.